OPDP Reflects on 2020, Looks Forward to 2021 as It Helps Ensure Prescription Drug Promotion Is Truthful, Balanced and Accurate
FDA’s Center for Drug Evaluation and Research’s (CDER) Office of Prescription Drug Promotion (OPDP) works to help ensure that prescription drug promotion is truthful and not misleading. It does so through comprehensive surveillance, compliance, policy, and education programs. The office also fosters better communication of drug labeling and promotional information to health care providers and the public.
In this CDER Conversation, Katie Gray, Pharm.D., acting OPDP director, speaks about the office’s 2020 achievements and 2021 goals, its COVID-19 response, and the ways OPDP continues to streamline operations to fulfill its public health mission.